摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 2-bromo-4H-thieno[3,2-b]pyrrole-5-carboxylate | 1283737-10-9

中文名称
——
中文别名
——
英文名称
methyl 2-bromo-4H-thieno[3,2-b]pyrrole-5-carboxylate
英文别名
2-bromo-4H-thieno[3,2-b]pyrrole-5-carboxylic acid methyl ester
methyl 2-bromo-4H-thieno[3,2-b]pyrrole-5-carboxylate化学式
CAS
1283737-10-9
化学式
C8H6BrNO2S
mdl
MFCD15730637
分子量
260.111
InChiKey
ZZUSKBHHRZULEI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    392.0±37.0 °C(Predicted)
  • 密度:
    1.788±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    70.3
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Synthesis and Properties of Semiconducting Bispyrrolothiophenes for Organic Field-Effect Transistors
    作者:Crystalann Jones、Damien Boudinet、Yu Xia、Mitch Denti、Adita Das、Antonio Facchetti、Tom G. Driver
    DOI:10.1002/chem.201304914
    日期:2014.5.12
    highly soluble bispyrrolothiophenes were synthesized from vinyl azides by using transition‐metal‐catalyzed CH‐bond functionalization. In addition to modifying the substituents present on the end‐pyrrolothiophene moieties, the arene linker in between the two units was also varied. The solution‐state properties and field‐effect‐transistor (FET) electrical behavior of these bispyrrolothiophenes was compared
    一系列新的高度可溶性bispyrrolothiophenes通过使用过渡属催化的C来自乙烯基叠氮化物的合成氢键官能化。除了修饰存在于吡咯噻吩末端的取代基外,两个单元之间的芳烃连接基也发生了变化。比较了这些双吡咯噻吩的溶液状态性质和场效应晶体管(FET)的电性能。我们的研究表明,我们化合物的光学性质和氧化潜能主要由具有最大λ的吡咯噻吩单元决定。 大约400 nm的电导率和大约1 V的氧化值。用这些双吡咯噻吩的薄膜构造的FET器件也通过薄膜溶液处理来制造。这些化合物之一是与苯并基二唑连接的双吡咯噻吩,其迁移率约为0.3 cm 2  V -1  s -1,I on / I off值大于10 6。
  • MODULATORS OF ALPHA-1 ANTITRYPSIN
    申请人:Vertex Pharmaceuticals Incorporated
    公开号:US20200361939A1
    公开(公告)日:2020-11-19
    The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.
    该披露提供了用于治疗α-1抗胰蛋白酶缺乏症(AATD)的化合物,其化学式为(I):它们的互变异构体,这些化合物的药用盐,这些互变异构体的药用盐,这些化合物的代衍生物,这些互变异构体的代衍生物,以及这些盐的代衍生物,这些化合物的固态形式以及制备这些化合物的方法。
  • [EN] CONDENSED TRYCICLIC PYRROLES AS ALPHA-1 ANTITRYPSIN MODULATORS<br/>[FR] PYRROLES TRICYCLIQUES CONDENSÉS UTILISÉS COMME MODULATEURS DE L'ALPHA-1 ANTITRYPSINE
    申请人:VERTEX PHARMA
    公开号:WO2020247160A1
    公开(公告)日:2020-12-10
    The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I), tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.
  • [EN] SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROARYLE BICYCLIQUES SUBSTITUÉS
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2021067326A1
    公开(公告)日:2021-04-08
    Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein X, Y, A, G, R1, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
  • [EN] ZWITTERIONIC ANTIBACTERIAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIBACTÉRIENS ZWITTERIONIQUES
    申请人:[en]F. HOFFMANN-LA ROCHE AG
    公开号:WO2023161316A1
    公开(公告)日:2023-08-31
    The invention provides novel imidazole pyrazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein A, X, R1-R9, R12and R13are as described herein (I). Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.
查看更多

同类化合物

N-甲基-n-[(4-甲基-4H-噻吩并[3,2-b]吡咯-5-基)甲基]胺盐酸盐 6H-噻吩并[2,3-b]吡咯-5-羧酸甲酯 6H-噻吩并[2,3-b]吡咯-5-羧酸乙酯 6H-噻吩并[2,3-b]吡咯-5-羧酸 6-[(3-氨基苯基)甲基]-4,6-二氢-4-甲基-2-(甲基亚磺酰)-5H-噻吩并[2',3':4,5]吡咯并[2,3-D]哒嗪-5-酮 4H-噻唑[3,2-B]吡咯-5-甲酸 4H-噻吩并[3,4-B]吡咯-2,5-二羧酸二乙酯 4H-噻吩并[3,2-b]吡咯-5-羧酸甲酯 4H-噻吩并[3,2-b]吡咯,6-(甲基亚硫酰基)-5-(甲硫基)- 4H-噻吩并[3,2-B]吡咯-5-甲酰肼 4H-噻吩并[3,2-B]吡咯-5-甲酰氯 4H-噻吩并[3,2-B]吡咯-2-羧酸 4H-噻吩[3,2-b]吡咯-5-羧酸乙酯 4H-Dithieno[3,2-b:2',3'-d]吡咯,4-(1-辛基壬基)- 4-(Tridecan-7-基)-4H-二硫代[3,2-b:2',3'-d]吡咯 4-辛基-4H-二噻吩并[3,2-b:2,3-d]吡咯 4-甲基-4H-噻吩并[3,2-b]吡咯-5-羧酸甲酯 4-甲基-4H-噻吩并[3,2-b]吡咯-5-羧酸乙酯 4-甲基-4H-噻吩并[3,2-b]吡咯-5-羧酸 4-甲基-4H-噻[3,2-B]吡咯-5-甲醛 4-R-4H-二噻吩并[3,2-b:2',3'-d]吡咯 4-(2-乙基己基)-4H-二噻吩并[3,2-b:2,3-d]吡咯 3-甲酰基-4H-噻吩并[3,2-B]吡咯-5-羧酸乙酯 3-甲基-4H-噻吩并[3,2-B]吡咯-5-羧酸乙酯 3-溴-4H-噻吩并[3,2-b]吡咯-5-羧酸乙酯 3-溴-4H-噻吩并[3,2-b]吡咯-5-羧酸 3-溴-4H-噻吩并[3,2-B]吡咯-5-羧酸甲酯 3-氯-4H-噻吩并[3,2-b]吡咯-5-羧酸 3-二氯乙酰基-2-甲基-4H-噻吩并[3,2-b]吡咯-5-羧酸甲酯 2-甲酰基-4H-噻吩并[3,2-B]吡咯-5-羧酸乙酯 2-甲基-4H-噻吩并[3,2-b]吡咯-5-羧酸乙酯 2-甲基-4H-噻吩并[3,2-b]吡咯-5-羧酸 2-溴-6-甲酰基-4H-噻吩并[3,2-b]吡咯-5-羧酸乙酯 2-溴-6-甲酰基-4-甲基-4H-噻吩并[3,2-B]吡咯-5-羧酸乙酯 2-溴-4H-噻吩并[3,2-b]吡咯-5-羧酸乙酯 2-溴-4,6-二氢-4-甲基-5H-噻吩并[2,3:4,5]吡咯并[2,3-d]吡嗪-5-酮 2-氯-6H-噻吩并[2,3-b]吡咯-5-羧酸乙酯 2-氯-6H-噻吩并[2,3-B]吡咯-5-羧酸甲酯 2-氯-4H-噻吩并[3,2-b]吡咯-5-羧酸甲酯 2-氯-4H-噻吩并[3,2-b]吡咯-5-羧酸乙酯 2-氯-4H-噻吩并[3,2-b]吡咯-5-羧酸 2-氯-3-甲基-4H-噻吩并[3,2-B]吡咯-5-羧酸乙酯 2-三丁基锡-4-(2-乙基己基)-4H-二噻吩并[3,2-B:2,3-D]吡咯 2,6-二溴-4-正辛基二噻吩并[3,2-b:2',3'-d]吡咯 2,6-二溴-4-(2-乙基己基)-4H-二噻吩并[3,2-b:2,3-d]吡咯 2,3-二氯-4H-噻吩并[3,2-b]吡咯-5-羧酸 (4-甲基-4H-噻吩并[3,2-b]吡咯-5-基)甲醇 (4-(叔丁氧基羰基)-2-氯-4H-噻吩并[3,2-B]吡咯-5-基)硼酸 (2,3-dimethyl-4H-thieno[3,2-b]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone (2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone